OM DENNE EPISODE
In this special Crimes Against Innovation episode, host Nicola Hill hears two charges against the research system.
Professor Raj Chovatiya argues that the academic model is putting the brakes on innovation, squeezing creativity and collaboration. Meanwhile, Dr Joe Rastrick condemns the irreproducible published study, which can misdirect future research and waste resources.
Join the debate and decide which crime should carry the greater sentence.
Hosted on Acast. See acast.com/privacyhttps://acast.com/privacy for more information.
This podcast is produced and funded by UCB.
GL-OT-2600004 – May 2026
Hosted on Acast. See acast.com/privacy for more information.
Engelsk
USA
UDSKRIFT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
SØG BLANDT TIDLIGERE EPISODER
Søg efter gamle afsnit af Hypothesize That!.
ANDRE EPISODE I DENNE PODCAST
In the darkened corridors of laboratories and the silent pages of medical journals, there are stories rarely spoken about—tales of brilliance that burned too bright, and ideas that strayed into catastrophe. This is—Crimes Against Innovation.
Laurence Woollard and Dr. Emma Lane debate two pre…
Deep in the shadowy corridors of laboratories and the silent pages of medical journals, progress can falter, not for lack of brilliance, but because of the systems surrounding it. Ideas are delayed, discoveries are hidden, and bold thinking is quietly discouraged. This is Crimes Against Innovation.…
Are today’s clinical trials fit for the future of medicine, or are they holding innovation back?
In this episode, host Nicola Hill, is joined by Professor Maddie Parsons, Dean of Research Excellence Frameworks at King’s College London, and Dr Graham Price, Head of Global Clinical Developme…
In this episode, we ask a defining question: will multi-specific therapies revolutionize how we treat complex diseases? Host Nicola Hill is joined by Dr Joe Rastrick (UCB) and Professor Raj Chovatiya (Rosalind Franklin University) to examine whether medicines engineered to target multiple pathways …
Ansvarsfraskrivelse: Podcasten og kunstværket, der er indlejret på denne side, er fra UCB Biopharma, som tilhører dens ejer og ikke er tilknyttet eller godkendt af Listen Notes, Inc.
REDIG
Tak fordi du hjælper med at holde podcast-databasen opdateret.
